Stevanato Group presents a webinar on:
Exploring best practices in visual inspection for Difficult-to-Inspect Products
- Date: Tuesday, June 16th
- Time: 4.00 PM CEST
- Duration: 1 hour
An array of protein-based therapies is being launched in the market for an increasing range of application treatments. These products typically present as difficult to inspect, they characterize as dense emulsions and suspensions, lyophilized or unstable complex biotech drugs (mAbs) to quote a few.
Difficult-to-inspect products (DIP) call for new challenges, requiring vendors operating in the pharma visual inspection to master inspection technologies to ensure product integrity, for patients’ safety. Contrary to current belief, Automatic Visual Inspection for these drugs can be successfully implemented and support pharma companies to reach their productivity goals.
This webinar will provide a platform to illustrate the latest techniques available today and how Stevanato Group is addressing these challenges. Through best practices we will cover results obtained in the inspection of a comprehensive range of difficult-to-inspect products. The discussion will also address the emergence of Artificial Intelligence and the results it can deliver.
Key Learning Objectives:
- Key trends and challenges in the visual inspection market
- Best practices related to different DIP drugs:
- Heavy suspensions
- Milky products
- Introduction to Artificial Intelligence and preliminary on-field results
Who Should Attend:
- Operations Managers
- Process and Production Engineers
- Visual Inspection Process Engineers
- Visual Inspection Managers
- Vision Subject Matter Experts (SMEs)
About the speakers:
Dr Andrea Sardella
Pharma Inspection Product Development Manager - Stevanato Group
Degree in Physics at Padua University in 1989, master in Nuclear Engineering in the 1990. As researcher at the National Research Council (C.N.R.) he developed several optoelectronic and nuclear scientific instruments for Magnetically Controlled Fusion Research setting up international collaboration with UWA Madison (USA) and Garchin IPP (De). After 10 years of activity in research he moved to the industrial sector developing optical and vision controls for industrial application as CEO of a Tattile srl subsidiary, now Antares Vision. This experience drove him into the pharmaceutical field, where he started to develop several control applications with vision and spectroscopy tools. After several years he joined Brevetti C.E.A spa as R&D Manager where he developed innovative inspection technology for the inspection machines. Since 2008 he has been with Stevanato Group as R&D Manager to develop new automation and inspection products dedicated to the pharmaceutical customers of the group.